ChromaDex' pTeroPure® Achieves GRAS Status

IRVINE, Calif., June 7, 2011 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC) today announced that an independent scientific panel of experts supports the GRAS (generally recognized as safe) status of its ingredient pTeroPure®. pTeroPure is an ultra-pure formulation of the naturally occurring compound pterostilbene, found in blueberries. pTeroPure has the potential to impact heart health by supporting cholesterol and blood pressure while providing additional benefits related to cognitive function and healthy aging .By achieving GRAS status, ChromaDex can now expand pTeroPure into the food and beverage industry, moving beyond the supplement industry where it has recently been incorporated in more than 20 nutraceutical products.

Following a comprehensive review of the safety, toxicology and proposed usage, an independent panel of experts reached a unanimous decision that pTeroPure is safe for use in food and beverage products. GRAS is a U.S. Food and Drug Administration (FDA) designation that an ingredient in food is considered safe by experts. The Allowable Daily Intake (ADI) for pTeroPure is up to 30mg/kg (or 1.89 grams) per day for food use and intake.

"The industry experts from the American Institute for Biosocial and Medical Research, including former U.S. Department of Agriculture and FDA staffers, all agreed that pTeroPure merits this designation," remarked Frank Jaksch, CEO of ChromaDex, Inc. "Their acceptance of GRAS for pTeroPure is a testament to the extensive scientific research for pterostilbene in general and the exceptional technical information that demonstrates the safety of pTeroPure in particular."

The first human clinical trial to evaluate pTeroPure is currently underway at the University of Mississippi to evaluate the compound in patients with lipid (cholesterol) disorders. The primary outcome includes standard lipid laboratory markers (HDL, LDL and triglycerides), and secondary endpoints include blood pressure, markers of oxidative stress, and safety. ChromaDex holds exclusive worldwide patent rights for pterostilbene based on technology licensed from the University of Mississippi and the USDA.

William Spengler, President, ChromaDex, Inc. states, "Achieving GRAS status for pTeroPure provides a significant new commercial opportunity for the Company to enter the multi-billion dollar market segment for natural food and beverage ingredients. Based on a scientific foundation, we are seeking to establish a leadership role for pTeroPure in the rapidly growing market for health and wellness."

pTeroPure was recently named the 2010 North American Most Promising Ingredient of the Year by the prestigious independent research company, Frost & Sullivan. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets. For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694.

About ChromaDex

ChromaDexis an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries.  The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.  

ChromaDex Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
[email protected]

pTeroPure Contact
Jeremy Bartos
Product Development Manager
949-600-9694
[email protected]

ChromaDex Contact
Laura Carney
Administrative Assistant
949-419-0288
[email protected]

Media Inquiries:
Carolyn Hawley
Canale Communications
619-849-5375
[email protected]

SOURCE ChromaDex Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED